EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

Pathways to translation for nanomedicine in nephrology

Zoe Schoales, Pratyusha Ghosh, Anastasiia Vasylaki, Edgar A Jaimes iD, Ryan Williams

Clinical Kidney Journal · 01.09.2025 · 18 (9)

DOI: 10.1093/ckj/sfaf192 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical Kidney Journal, online erschienen am 18.09.2025. Verfasst von Zoe Schoales und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, City College of New York, New York, NY, USA. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 201 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NIMHD NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kidney diseases are a substantial worldwide health burden, with high mortality and increasing incidence. Despite their prevalence, substantial gaps remain in the clinic in both diagnostics and therapeutics. Many novel treatments have failed in clinical trials or fallen out of use in the clinic due to side effects and poor efficacy, in large part due to poor therapeutic profiles in the kidney. Nanomedicines have begun to emerge as a potentially promising diagnostic or therapeutic delivery system. Based on their physicochemical properties, such as size, shape, surface chemistry, and so on, some nanotechnologies can target the kidneys. However, as of yet, no kidney-specific nanomedicines have reached clinical translation. While the field of renal nanomedicine is in its early stages and growing, some potential obstacles to translation include poor preclinical models, challenges in manufacturing scale-up, clinical trial design and the cost of translation. Here, we overview the current state of the kidney-targeting nanomedicine field and outline a potential framework for clinical translation. We focus on the paths of US Food and Drug Administration– approved nanomedicines and suggestions from other nanomedicine fields to inform our key considerations for translational success. We also highlight the importance of academic and clinical collaboration with industry and federal regulators. Several investigational technologies are just now at the cusp of scaling towards the clinic and we therefore aim to support this momentum for improving the lives of patients with kidney diseases.

Schlagwörter

Stichwörter der Autor:innen

drug deliveryimagingkidney targetingnanomedicinepreclinical development

Autor:innen und Institutionen

  • Department of Biomedical Engineering, City College of New York, New York, NY, USA.
  • Memorial Sloan Kettering Cancer Center, New York, NY, USA.

ORCID-Profile: Edgar A Jaimes

Förderung

  • NCI NIH HHS
  • NIMHD NIH HHS
  • National Institutes of Health
  • Department of Education Research and Development Infrastructure

Zitieren

APA

Schoales, Z., Ghosh, P., Vasylaki, A., Jaimes, E. A., & Williams, R. (2025). Pathways to translation for nanomedicine in nephrology. Clinical Kidney Journal, 18(9). https://doi.org/10.1093/ckj/sfaf192

Vancouver

Schoales Z, Ghosh P, Vasylaki A, Jaimes EA, Williams R. Pathways to translation for nanomedicine in nephrology. Clinical Kidney Journal. 2025;18(9). doi:10.1093/ckj/sfaf192

BibTeX
@article{Schoales2025,
  author = {Schoales, Zoe and Ghosh, Pratyusha and Vasylaki, Anastasiia and Jaimes, Edgar A and Williams, Ryan},
  title = {Pathways to translation for nanomedicine in nephrology},
  journal = {Clinical Kidney Journal},
  year = {2025},
  volume = {18},
  number = {9},
  doi = {10.1093/ckj/sfaf192}
}
Kostenlos starten →